BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang G, Li R, Deng Y, Zhao L. Conditional survival of patients with hepatocellular carcinoma: results from the Surveillance, Epidemiology, and End Results registry. Expert Rev Gastroenterol Hepatol 2018;12:515-23. [PMID: 29543072 DOI: 10.1080/17474124.2018.1453806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Taye BW, Clark PJ, Hartel G, Powell EE, Valery PC. Remoteness of residence predicts tumor stage, receipt of treatment, and mortality in patients with hepatocellular carcinoma. JGH Open 2021;5:754-62. [PMID: 34263069 DOI: 10.1002/jgh3.12580] [Reference Citation Analysis]
2 Furuke H, Konishi H, Arita T, Kataoka S, Shibamoto J, Takabatake K, Takaki W, Shimizu H, Yamamoto Y, Morimura R, Komatsu S, Shiozaki A, Ikoma H, Otsuji E. miR‑4730 suppresses the progression of liver cancer by targeting the high mobility group A1 pathway. Int J Mol Med 2022;49:83. [PMID: 35485281 DOI: 10.3892/ijmm.2022.5139] [Reference Citation Analysis]
3 Li H, Wang M, Zhou H, Lu S, Zhang B. Long Noncoding RNA EBLN3P Promotes the Progression of Liver Cancer via Alteration of microRNA-144-3p/DOCK4 Signal. Cancer Manag Res 2020;12:9339-49. [PMID: 33061623 DOI: 10.2147/CMAR.S261976] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
4 Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Deuker M, Mistretta FA, Tian Z, Fossati N, Gallina A, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. J Surg Oncol 2020;121:1154-61. [PMID: 32107785 DOI: 10.1002/jso.25877] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Reference Citation Analysis]
6 Ye Y, An Y, Wang M, Liu H, Guan L, Wang Z, Li W. Expression of Carboxypeptidase X M14 Family Member 2 Accelerates the Progression of Hepatocellular Carcinoma via Regulation of the gp130/JAK2/Stat1 Pathway. Cancer Manag Res 2020;12:2353-64. [PMID: 32280274 DOI: 10.2147/CMAR.S228984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers (Basel) 2021;13:514. [PMID: 33572780 DOI: 10.3390/cancers13030514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
8 Lu W, Hong W, Qiu H, Zhou Z, He Z, Zeng W, Zhong W, Xie J. A novel prognostic time window based on conditional survival and outcomes analyses of primary liver cancer patients. Cancer Med 2022. [PMID: 35460212 DOI: 10.1002/cam4.4762] [Reference Citation Analysis]
9 Oura K, Morishita A, Masaki T. Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review. Int J Mol Sci 2020;21:E8362. [PMID: 33171811 DOI: 10.3390/ijms21218362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Qiu Q, Jiang L, Zhen H, Huang F, Zhen D, Ye M, Meng X, Liu Y, Qin X. Promotion of HepG2 cell apoptosis by Sedum emarginatum Migo and the mechanism of action. BMC Complement Med Ther 2022;22:31. [PMID: 35101006 DOI: 10.1186/s12906-022-03503-6] [Reference Citation Analysis]
11 Yang YL, Chang YH, Li CJ, Huang YH, Tsai MC, Chu PY, Lin HY. New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics. J Pers Med 2021;11:219. [PMID: 33803804 DOI: 10.3390/jpm11030219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li Z, Du S, Feng W, Zhang W, Li G, Wei J, Zhang G, Zhao L. Competing risks and cause-specific mortality in patients with pancreatic neuroendocrine tumors. Eur J Gastroenterol Hepatol 2019;31:749-55. [PMID: 30601340 DOI: 10.1097/MEG.0000000000001350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
13 Huang W, Chen Q, Dai J, Zhang Y, Yi Y, Wei X, Wu Z. miR-744-5p suppresses tumor proliferation and metastasis by targeting transforming growth factor-beta 1 (TGF-β1) in hepatocellular carcinoma (HCC). J Gastrointest Oncol 2021;12:1811-22. [PMID: 34532130 DOI: 10.21037/jgo-21-319] [Reference Citation Analysis]
14 Evangelista J, Zaninotto E, Gaglio A, Ghidini M, Raimondi L. MicroRNAs as Diagnostic Tools in Hepatocellular Carcinoma. GastrointestDisord 2021;3:237-46. [DOI: 10.3390/gidisord3040022] [Reference Citation Analysis]
15 Fernandes GDS, Campos D, Ballalai A, Palhares R, da Silva MRA, Palhares DMF, Neto BF, Barros FMDR, Gil RA, Chagas A, Carrilho FJ. Epidemiological and Clinical Patterns of Newly Diagnosed Hepatocellular Carcinoma in Brazil: the Need for Liver Disease Screening Programs Based on Real-World Data. J Gastrointest Cancer 2021;52:952-8. [PMID: 32918274 DOI: 10.1007/s12029-020-00508-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]